SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo)
DEPO 7.300+1.7%Aug 14 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: seminole who wrote (438)12/15/1997 2:45:00 PM
From: Sector Investor  Read Replies (3) of 887
 
From a COWEN report on Chiron:

Cowen says that data On CHIR/DEPO's DepoCyt Viewed As Marginal But Approvable - Recall that CHIR/DEPO's NDA for DepoCyt, a new formulation of cytarabine (a chemotherapy drug) for the treatment of neoplastic meningitis, is being reviewed by an FDA panel on December 18. Another look at the Phase III data and a chat with one of the investigators in the trial reinforced our view that while the data are not stellar, the drug will likely be approved based on its potential benefits to a patient population with limited treatment alternatives. A negative panel vote would hold limited downside to our CHIR model (our '98-01 revenue estimates for CHIR are modest at $10-30MM).

From a new release on 12/1 regarding FDA upcoming activities:

In the afternoon of the 18th, the committee will discuss DepoTech (DEPO-$15 1/8)/Chiron's (CHIR-$18 1/16) DepoCyt(R) (cytarabine), an anti-cancer treatment for patients with neoplastic meningitis. Neoplastic meningitis is a secondary form of cancer that occurs in patients with solid tumors, lymphoma or leukemia. About 65,000 cases occur annually in the U.S. DepoCyt(R) is an injectable sustained-release formulation of a chemotherapy agent.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News